Website
CSL LimitedTelephone
61.3.9389.1911
Address
655 Elizabeth Street Melbourne, Victoria (VIC) 3000
Description
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 228.65 - 312.99
Trade Value (12mth)
US$35,178,785.00
1 week
0.91%
1 month
-2.2%
YTD
-4.34%
1 year
-8.1%
All time high
342.75
EPS 3 yr Growth
0.500%
EBITDA Margin
28.60%
Operating Cashflow
$2,601m
Free Cash Flow Return
11.20%
ROIC
9.60%
Interest Coverage
8.50
Quick Ratio
0.80
Shares on Issue (Fully Dilluted)
485m
HALO Sector
Healthcare
Next Company Report Date
13-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.32
Date | Announcements |
---|---|
03 May 24 |
Notification of cessation of securities - CSL
×
Notification of cessation of securities - CSL |
23 April 24 |
Shareholder Information Meetings
×
Shareholder Information Meetings |
11 April 24 |
CSL Australia Investor Site Tour Presentations
×
CSL Australia Investor Site Tour Presentations |
08 April 24 |
Publication of AEGIS II Trial Data
×
Publication of AEGIS II Trial Data |
05 April 24 |
Notification of cessation of securities - CSL
×
Notification of cessation of securities - CSL |
27 March 24 |
CSL prices US$1.25 billion in Corporate Bonds
×
CSL prices US$1.25 billion in Corporate Bonds |
19 March 24 |
Change in substantial holding
×
Change in substantial holding |
14 March 24 |
Update - Dividend/Distribution - CSL
×
Update - Dividend/Distribution - CSL |
08 March 24 |
Application for quotation of securities - CSL
×
Application for quotation of securities - CSL |
07 March 24 |
Notification of cessation of securities - CSL
×
Notification of cessation of securities - CSL |
05 March 24 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
04 March 24 |
Application for quotation of securities - CSL
×
Application for quotation of securities - CSL |
23 February 24 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
23 February 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
16 February 24 |
Notification regarding unquoted securities - CSL
×
Notification regarding unquoted securities - CSL |
16 February 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
13 February 24 |
Statutory Accounts for the Half Year Ended 31 December 2023
×
Statutory Accounts for the Half Year Ended 31 December 2023 |
13 February 24 |
Half Year Results Announcement
×
Half Year Results Announcement |
13 February 24 |
Dividend/Distribution - CSL
×
Dividend/Distribution - CSL |
13 February 24 |
Half Year Results Investor Presentation
×
Half Year Results Investor Presentation |
13 February 24 |
Update - Dividend/Distribution - CSL
×
Update - Dividend/Distribution - CSL |
12 February 24 |
Top-line Results from the Phase 3 AEGIS-II Trial
×
Top-line Results from the Phase 3 AEGIS-II Trial |
06 February 24 |
Notification of cessation of securities - CSL
×
Notification of cessation of securities - CSL |
30 January 24 |
Notice of Investor/Analyst Briefing 2024 Half Year Results
×
Notice of Investor/Analyst Briefing 2024 Half Year Results |
09 January 24 |
Notification of cessation of securities - CSL
×
Notification of cessation of securities - CSL |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.